| Literature DB >> 34868943 |
Xue-Ying Zhu1, Zhong Li1, Cong Chen2, Ru-Li Feng2, Bai-Ru Cheng2, Ruo-Yi Liu3, Rui-Ting Wang2, Li Xu4, Yue Wang5, Xin Tao6, Peng Zhao2.
Abstract
OBJECTIVE: To evaluate the effects of Physical Therapies (PTs) on improvement in psychosomatic symptoms and quality of life (QOL) in breast cancer patients. DATA SOURCES: Seven databases (MEDLINE, EMBASE, Cochrane CENTRAL, China National Knowledge Infrastructure, Wangfang, VIP, and China Biology Medicine disc databases) were systematically searched from the database inception through May 18, 2021. STUDY SELECTION: Randomized controlled trials (RCTs) which compared acupuncture or exercise with a sham control or usual care for the treatment of aromatase inhibitors (AIs)-related psychosomatic symptoms and QOL. DATA EXTRACTION AND SYNTHESIS: Data were screened and extracted independently using predesigned forms. The quality of RCTs was assessed with the Cochrane Handbook for Systematic Reviews of Interventions. The effect size was calculated via random-effects modeling. The quality of evidence was evaluated with the Grading of Recommendations Assessment, Development and Evaluation approach. MAIN OUTCOMES AND MEASURES: The score of pain was measured with BPI scale and Western Ontario and the McMaster Universities Index (WOMAC) scale. Emotional state was measured with Pittsburgh Sleep Quality Index (PSQI), Hospital Anxiety and Depression Scale (HADS-A), and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue). The QOL score was measured by self-reported measurements, including the Functional Assessment of Cancer Therapy-General (FACT-G) scale and 36-Item Short Form Survey (SF-36) scale.Entities:
Keywords: acupuncture; aromatase inhibitors; breast cancer; exercise; pain; physical therapies; quality of life
Year: 2021 PMID: 34868943 PMCID: PMC8632958 DOI: 10.3389/fonc.2021.745280
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flow diagram.
Characteristics of trials included in the analysis.
| Source* | Intervention | Trial design | Sample size (I/C) | Age (I/C) | Arms (course) | Participant characteristics | Race | Outcome measurement tool | Primary outcome result |
|---|---|---|---|---|---|---|---|---|---|
| Crew et al. ( | MA | Sham-controlled | 43 (23/20), 5 (3/2) | 58 (44–77)/57 (37–77) | TA/SA (30 min twice weekly, 6 wk) |
Postmenopausal Stage I–III breast cancer Estrogen receptor-positive, progesterone receptor-positive, or both AI for 3 months Pain score on the BPI-SF of ≥3 points | White (39%), Hispanic (55%), Black (3%), Asian (3%) |
BPI-SF WOMAC M-SACRAH FACT-G | Positive |
|
| 2-arm | ||||||||
| Oh et al. ( | EA | Sham-controlled | 32 (16/16), 3 (2/1) | <45 14 (93%) and ≥45 1 (7%)/<45 12 (86%) and ≥45 2 (14%) | TA/SA (30 min twice weekly, 6 wk) |
Postmenopausal Stage I–IIIa breast cancer Estrogen receptor-positive, progesterone receptor-positive, or both AI for 6 months Pain score on the BPI-SF of points | Caucasian (86%), Others (14%) |
BPI-SF WOMAC FACT-G Blood analysis: CRP, ESR | Positive |
|
| 2-arm | ||||||||
| Mao et al. ( | EA | Sham-controlled | 67 (22/22/23), 8 (3/3/2) | 57.5 ± 10.1/60.9 ± 6.5/60.6 ± 8.2 | TA/SA/WLC (twice a week for 2 wk; then weekly for 6 wk) |
Stage I–III breast cancer AI for 3 months Joint pain ≥3 months Numerical rating scale ≥4 points At least15 days with pain in the preceding 30 days | White (72%), Others (28%) |
BPI WOMAC DASH PPT Fatigue: BFI Sleep: PSQI Anxiety: HADS Depression: HADS-Depression | Positive |
|
| 3-arm | ||||||||
| Bao et al. ( | MA | Sham-controlled | 51 (25/26), 4 (2/2) | 61 (44–82)/61(45–85) | TA/SA (8 weekly for 8 wk) |
Postmenopausal Stage I–III breast cancer AI for 1 month Baseline HAQ-DI score ≥3 and/or pain using a 100-point VAS ≥20 Have not received acupuncture treatment in the past 12 months | Caucasian (72%), African American (19%), Other (9%) |
HAQ-DI VAS β-endorphin; estradiol; Proinflammatory cytokines: IL-1, -6, -8, -10, -12, -17, IFN-γ, TNF-α Menopausal symptoms: NSABP Hot Flash: HFRDI Sleep: PSQI Depression: CESD Anxiety:HADS-A, Quality of life: Euro Qol | Negative |
|
| 2-arm | ||||||||
| Hershman et al. ( | MA | Sham-controlled | 226 (110/59/57), 20 (9/5/6) | 60.8 (34.1–80.6)/57.0 (40.6–77.5)/60.6 (27.1–76.0) | TA/SA/WLC (twice a week for 6 wk; then weekly for 6 wk) |
Postmenopausal or premenopausal with gonadotropin-releasing hormone agonist Stages I–III breast cancer Estrogen receptor-positive, progesterone receptor-positive, or both AI ≥ 1 month to continue for at least 1 additional year Zubrod performance 0–1 Pain score on the BPI-SF of ≥3 points | White (85%), Black (4.4%), Asian (6.6%), Pacific Islander (0.4%), American Indian (0.4%), others (3.2%) |
BPI WOMAC PROMIS PI-SF M-SACRAH FACT-ES | Positive |
|
| 3-arm | ||||||||
| Baker et al. ( | EX (Low-frequency, low-magnitude vibrative) | Open label-controlled | 31 (14/17), 0 | 61.6 ± 9.2/61.6 ± 7.8 | EX/WLC (20 min of vibration, 3 weekly for 12 wk) |
Breast cancer (stage unknown) Taking any bone-altering medications or supplements Able to stand unassisted for sustained periods of time (i.e., 20 min) | Australian (100%) |
WOMAC FACT–Fatigue subscale Bone Resorption and Formation: NTx/Cr, P1NP Body Composition and Bone Mineral Density Physical Functioning | Negative |
|
| 2-arm | ||||||||
| Paulo et al. ( | EX (resistance training followed by aerobic training) | Open label-controlled | 36 (18/18), 7 (3/4) | 63.2 ± 7.1/66.6 ± 9.6 | EX/CG (3 weekly for 36 months) |
Aged between 50 and 80 years Stage I–III breast cancer AI for breast cancer No muscle and bone damage | Brazilians (100%) |
SF36 EORTC QLQ-C30 EORTC QLQ-BR23 | Positive |
|
| 2-arm | ||||||||
| Baglia et al. ( | EX (strength-training and aerobic exercise) | Open label-controlled | 121 (61/60), 38 (16/22) | 62 ± 7/60.5 ± 7 | EX/CG (2 weekly for 12 months) |
Postmenopausal women, HR-positive, stage I–III BC diagnosed 0.5–4 years prior to enrolment AI for 6 months Arthralgias for ≥2 months, with BPI-SF score≥3/10 4.Pre-existing joint pain allowed if worsened after AI Physically inactive: baseline <90 min exercise/week, no strength training | Non-Hispanic White (85%) |
FACT FACT-G FACT-B SF-36 FACIT-Fatigue | Positive |
| Hispanic (3%) | |||||||||
| African American (9%) | |||||||||
| Asian/Pacific Islander (2%) | |||||||||
| American Indian (1%) | |||||||||
|
| 2-arm | ||||||||
| Nyrop et al. ( | EX (Walk) | Open label-controlled | 62 (31/31), 9 (7/2) | 63.3 ± 6.9/64.4 ± 9.7 | EX/WLC (150 min weekly for 6 wk) |
Age >21 years Stage 0–III breast cancer AI for 4 weeks Pain score on the BPI-SF of ≥3 points Exercising ≤150 min per week | Caucasian (74%), Others (26%) |
VAS WOMAC FACT‐G RAI ASE OEE SEPA | Positive |
|
| 2-arm | ||||||||
| Fields et al. ( | EX (Nordic walking) | Open label-controlled | 40 (20/20), 0 | 60 ± 8/66 ± 7 | EX/CG (once a week for 6 wk, then four times a week for 6 wk) |
Breast cancer (stage unknown) AI for breast cancer Reporting joint symptoms over preceding 12 months | Caucasian (100%) |
BPI-SF PSEQ CES-D SF-36 | Positive |
|
| 2-arm | ||||||||
| Irwin et al. ( | EX (strength-training and aerobic exercise) | Open label-controlled | 121 (61/60), 38 (16/22) | 62 ± 7/60.5 ± 7 | EX/CG (2 weekly for 12 months) |
Postmenopausal women, HR-positive, stage I–III BC diagnosed 0.5–4 years prior to enrolment AI for 6 months Arthralgias for ≥2 months, with BPI-SF score≥3/10 Pre-existing joint pain allowed if worsened after AI Physically inactive: baseline <90 min exercise/week, no strength training | Non-Hispanic White (85%) |
BPI WOMAC DASH Grip strength | Positive |
| Hispanic (3%) | |||||||||
| African American (9%) | |||||||||
| Asian/Pacific Islander (2%) | |||||||||
| American Indian (1%) | |||||||||
|
| 2-arm |
*Sources of funding for the included studies are provided in the .
I/C, data of Intervention group/data of control group(s);
Different outcomes were reported in separate publications; the data were merged.
Primary results of comparisons (experimental intervention vs. sham control(s) and experimental intervention vs. waitlist control) were both positive.
NM, no mention; EA, electroacupuncture; MA, manual acupuncture; AI, aromatase inhibitor; TA, true acupuncture group; SA, sham acupuncture group; WLC, waitlist control; EX, exercise; CG, control group; BPI-SF, Brief Pain Inventory–Short Form; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; M-SACRAH, Modified Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands; FACT-G, Functional Assessment of Cancer Therapy–General; BFI, Brief Fatigue Inventory; PSQI, Pittsburgh Sleep Quality Index; HADS, Hospital Anxiety and Depression Scale; HAD-DI, The Health Assessment Questionnaire—the disability index; NSABP, National Surgical Adjuvant Breast and Bowel Project; HADS-A, Hospital Anxiety and Depression Scale—the anxiety subscale; PROMIS PI-SF, The PROMIS Pain Impact-Short Form; CES-D, Center for Epidemiological Studies Depression; PSEQ, Pain Self-Efficacy Questionnaire; DASH, The Disabilities of the Arm, Shoulder, and Hand questionnaire; PPT, The Physical Performance Test; BMI, body mass index; %FM, percent body fat; LBM, lean body mass; BMD, bone mineral density; FSI, Fatigue Symptom Inventory; AUSCAN, Australian/Canadian Hand Osteoarthritis Index; HFRDIS, Hot Flash Related Daily Interference Scale; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer questionnaire entitled “Quality of life Questionnaire version 3.0; EORTC QLQ-BR23, European Organization for Research and Treatment of breast cancer module; FACT-ES, Functional Assessment of Cancer Therapy—the endocrine subscale; FACT-B, Functional Assessment of Cancer Therapy–Breast cancer; FACIT-Fatigue, Functional Assessment of Chronic illness Therapy–Fatigue; SF-36, the MOS item short from health survey; VAS, visual analog scale; RAI, rheumatology attitudes index; ASE, arthritis self‐efficacy scale; OEE, outcome expectations from exercise; SEPA, self-efficacy for physical activity.
Figure 2Each “Risk of bias” item for each included study.
Figure 3Overall change of acupuncture trials in pain, combined using (1) BPI worst pain subscale and (2) WOMAC pain subscale.
Figure 4BPI Pain Severity score in acupuncture trials.
Figure 5BPI Pain-Related Interference score in acupuncture trials.
Figure 6Overall change of exercise trials in pain, combined using (1) BPI worst pain subscale and (2) WOMAC pain subscale.
Figure 7HADS-A subscale in acupuncture trials.
Figure 8PSQI subscale in acupuncture trials.
Figure 9FACIT-Fatigue subscale in exercise trials.
Figure 10SF-36 subscale in exercise trials.
Figure 11FACT-G subscale in exercise trials.
Figure 12The chronic pain of multiaxial hierarchical structure.